Trial Profile
A phase II, placebo controlled, double-blind, randomized, discontinuation study of lapatinib administered orally to subjects with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Bladder cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Uterine cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 19 Jan 2010 Actual initiation date changed from Jan 2007 to May 2007 as reported by ClinicalTrials.gov.
- 19 Jan 2010 Planned end date changed from 1 Oct 2010 to 1 Sep 2009 as reported by ClinicalTrials.gov.
- 10 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.